What’s in a Suffix? FDA’s Dilemma: How to Name Biologics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

After a courtroom victory against Amgen Inc. this summer, the last of the obstacles was removed for the first biosimilar agent—a white blood cell growth factor—to enter the U.S. market.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Paul Goldberg
Editor & Publisher

Login